| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Bali Muralidhar last filed a Form 4 in July 2025, as Director at XCUR. The filings on record cover 3 companies. Bali Muralidhar's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Bali Muralidhar a below-average insider score of 30/100, based on 12 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -75.5%.
At the last filing, the largest reported position was 1,792,518 shares of SPRB. Net of sales, the SPRB filings show accumulation of 200,000 shares.
Bali Muralidhar has 23 Form 4 filings on record from August 2019 to July 2025, across 3 companies: Spruce Biosciences (SPRB), 2020–2025; Director at OnKure Therapeutics (OKUR), 2021–2023; Director at Exicure (XCUR), 2019–2022.
The 28 reported transactions were 14 open-market purchases, 12 option or other derivative awards and 2 conversions.
Counted by filing, the open-market trades come to 11 purchases worth about $10.2M and no sales.
The largest open-market purchase was 200,000 shares of OKUR at an average $15.00 on April 13, 2021, about $3.0M. Twelve months later OKUR was down 77%.
Shares as reported in the last Form 4 for each company; the most recent is from July 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 | XCUR Exicure, Inc. | Director | Buy | 1,472,126 | $0.19 | $285,150.81 | +21.1% | -37.2% | -73.3% | |
| Jul 14, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 111,736 | $8.50 | $949,756.00 | +5.7% | -22.3% | -65.2% | |
| Jun 23, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 20,710 | $9.28 | $192,244.72 | +1.1% | -18.7% | -75.9% | |
| Jun 22, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 47,274 | $8.94 | $422,413.74 | +2.5% | -11.4% | -74.8% | |
| Jun 8, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 16,605 | $9.50 | $157,709.31 | +0.9% | -7.8% | -76.1% | |
| Jun 4, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 12,357 | $9.26 | $114,365.17 | +0.7% | -6.4% | -77.1% | |
| May 28, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 14 | $9.50 | $133.00 | - | -37.5% | -79.3% | |
| May 27, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 7,035 | $9.36 | $65,864.42 | +0.4% | -27.1% | -78.5% | |
| Apr 13, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | +12.1% | -26.7% | -77.4% | |
| Oct 14, 2020 | SPRB Spruce Biosciences, Inc. | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | +12.6% | - | - |